Journal article
Combination of the probiotics Lacticaseibacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis, BB-12 has limited effect on biomarkers of immunity and inflammation in older people resident in care homes: Results from the Probiotics to Reduce Infections iN CarE home reSidentS Randomized, Controlled Trial
- Abstract:
- Aging is associated with a decline in many components of the immune system (immunosenescence). Probiotics may improve the immune response in older people. The objective was to determine the effect of the combination of two probiotic organisms [Lacticaseibacillus (previously known as Lactobacillus) rhamnosus GG (LGG) and Bifidobacterium animalis subsp. lactis, BB-12 (BB-12)] on a range of immune biomarkers measured in the blood of older people resident in care homes in the UK. In a randomized controlled trial, older people [aged 67–97 (mean 86) years] resident in care homes received the combination of LGG+BB-12 (1.3–1.6 × 109 CFU per day) or placebo for up to 12 months. Full blood count, blood immune cell phenotypes, plasma immune mediator concentrations, phagocytosis, and blood culture responses to immune stimulation were all measured. Response to seasonal influenza vaccination was measured in a subset of participants. Paired samples (i.e., before and after intervention) were available for 30 participants per group. LGG and BB-12 were more likely to be present in feces in the probiotic group and were present at higher numbers. There was no significant effect of the probiotics on components of the full blood count, blood immune cell phenotypes, plasma immune mediator concentrations, phagocytosis by neutrophils and monocytes, and blood culture responses to immune stimulation. There was an indication that the probiotics improved the response to seasonal influenza vaccination with significantly (p = 0.04) higher seroconversion to the A/Michigan/2015 vaccine strain in the probiotic group than in the placebo group (47 vs. 15%).
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, 458.1KB, Terms of use)
-
- Publisher copy:
- 10.3389/fimmu.2021.643321
Authors
- Publisher:
- Frontiers Media
- Journal:
- Frontiers in Immunology More from this journal
- Volume:
- 12
- Article number:
- 643321
- Publication date:
- 2021-03-04
- Acceptance date:
- 2021-02-12
- DOI:
- EISSN:
-
1664-3224
- Pmid:
-
33746986
- Language:
-
English
- Keywords:
- Pubs id:
-
1169375
- Local pid:
-
pubs:1169375
- Deposit date:
-
2021-04-22
Terms of use
- Copyright holder:
- VM Castro-Herrera et al.
- Copyright date:
- 2021
- Rights statement:
- © 2021 Castro-Herrera, Fisk, Wootton, Lown, Owen-Jones, Lau, Lowe, Hood, Gillespie, Hobbs, Little, Butler, Miles and Calder. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record